和晶泰一起
探索 AI + 机器人新旅程

全球办公室
01
AI generative
molecular designs
AI compound generations enable the possibility to explore ultra large chemical space, cover most of molecular design scenarios and generation strategies.
02
High throughput
Highly efficient algorithms and mass allocation of computational resources on the cloud
01
全球办公室

晶泰在中国北京、上海、深圳,美国波士顿地区,英国利物浦地区设立办公室

中国

深圳

深圳市福田区红柳道2号国际生物医药产业园二期三层

 +86-0755-81901777

上海

上海市浦东新区环桥路207号

+86-021-68780786

北京

北京市海淀区原点大厦B座706

+86-010-53604927

美国

波士顿地区

100 Chestnut Street, Fl 3, Somerville, MA 02143 ​

英国

利物浦地区

The Heath Business & Technical Park, Runcorn, WA7 4QX. United Kingdom.
合作咨询
01
AI generative
molecular designs
AI compound generations enable the possibility to explore ultra large chemical space, cover most of molecular design scenarios and generation strategies.
02
High throughput

Highly efficient algorithms and mass allocation of computational resources on the cloud

02
业务合作咨询

我们欢迎您通过上方的联系表单,或者下方的联系方式联系我们的顾问

Email

电话

Headquarters

Accurate across various targets with the state-of-the-art molecular force field
投资者关系
01
AI generative
molecular designs
AI compound generations enable the possibility to explore ultra large chemical space, cover most of molecular design scenarios and generation strategies.
02
High throughput
Highly efficient algorithms and mass allocation of computational resources on the cloud
03
投资者关系

联系我们的投资者关系团队

Email

ir@xtalpi.com

网站

Headquarters

Accurate across various targets with the state-of-the-art molecular force field

其他咨询
01
AI generative
molecular designs
AI compound generations enable the possibility to explore ultra large chemical space, cover most of molecular design scenarios and generation strategies.
02
High throughput
Highly efficient algorithms and mass allocation of computational resources on the cloud
04
其他问题咨询

关于媒体发布、渠道合作、廉洁举报等其他问题,欢迎通过以下方式联系我们

媒体合作

其他问题

最新发布
晶泰科技旗下Ailux任命Maria G. Belvisi博士为首席科学官,持续升级全球研发布局
晶泰科技参与耀速科技超2亿元A轮融资,AI+器官芯片+自动化构建下一代药物研发基础设施
《上海证券报》整版刊发温书豪博士文章丨实验室科学智能:通用智能跃迁的黄金场域
晶泰AI赋能管线再迎临床转化:莱芒生物“千分之一”剂量CAR-T疗法获FDA临床批准